Don't rely on searching. Read the document.

Page 16

4.2. Phase 2/3 4.2.1. Phase 2/3 study design In Phase 2/3, a total of 4,526 participants 6 months through 4 years of age were randomized 2:1 to receive two doses of 3 µg BNT162b2 or placebo, 3 weeks apart.>

After reading through the 9 results tables, I think that the problem is the results were divided by age. Table 6 is for ages 6 - 23 months and table 8 for ages 2 - 4 years. The totals for those add up to the original 4526 and account for participant loss.

Not saying the study or the approval is legit, just this concern about losing 3000 subjects may not be legit.